By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel is largely bearish on both PFE and VZ, with concerns about PFE's pipeline risk and VZ's debt burden and potential margin compression from wireless price pressure.
Risk: VZ's debt servicing costs forcing a dividend cut due to elevated interest rates and potential margin compression from wireless price pressure.
Opportunity: PFE's late-stage pipeline candidates potentially lifting FCF coverage above 100% within two years.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Picking a good dividend stock for your portfolio can be challenging, especially when there are many attractive high-yielding options to choose from. And there's much more to consider than just the yield itself.
Below, I'll compare a couple of top dividend stocks: Pfizer (NYSE: PFE) and Verizon Communications (NYSE: VZ). While they're in different sectors, they both may be alluring options for dividend investors because they are blue chip stocks that have been known for generating plenty of dividend income over the years. Pfizer yields around 7.1% while Verizon's payout is closer to 6.7%. They also trade at less than nine times their expected future earnings (based on analyst expectations), making them attractive value buys.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
But which one is the better buy? Let's take a look at which one is superior when evaluating multiple criteria.
This is the crucial, first qualifying question to ask when evaluating dividend stocks. If the payout isn't safe, then nothing else really matters, because if it's in danger of being cut, the yield, track record, and dividend growth won't be of much comfort at that point.
Verizon's payout ratio based on earnings is around 67%. It's a good, healthy rate that you want to see from a quality dividend stock. Pfizer is a bit more complicated. Its payout ratio is more than 100%, but the reality is that its earnings are worse than they look due to acquisition-related expenses and non-cash items. This is where just looking at the payout ratio falls short.
In terms of cash flow, the story looks a bit better for Pfizer as its free cash flow has been more than the cash dividends the company has paid out in two of the past three quarters. It can fluctuate, but generally, the payout looks well-supported. Over the trailing 12 months, Pfizer's free cash has been a bit lower than the dividends it has paid out, but with the company in the midst of cutting costs, that should improve.
Pfizer's dividend looks reasonably safe, but it's clear that the edge here goes to Verizon, which has generated a massive $20 billion in free cash over the past four quarters, well above the $11.5 billion it has paid in dividends.
Having plenty of room to pay dividends is one thing, but some companies hoard the cash or use it for other purposes rather than paying dividends. For dividend investors, it's important to consider which company actively rewards its shareholders and is generous with the dividend. Both of these stocks have been raising their payouts over the years, but one has been increasing them at a far higher rate than the other.
The edge clearly goes to Pfizer here. But it's worth noting the big spike around 2021 when Pfizer generated a boatload of revenue from its COVID vaccine and pill, and the slowing down of its dividend growth rate recently. When taking that into account, plus the restructuring it's undertaking right now, it's not as overwhelming an advantage for Pfizer anymore; its rate of increases may be much more modest in the years ahead.
This is an important question to ask because when looking at dividend stocks, it's crucial to also consider where a business is headed. While the payout ratio and dividend growth rate may tell you about past results, that doesn't tell you anything about the future.
For Pfizer, the big risk is that the healthcare company is investing heavily in its future growth to offset losses in exclusivity. It might need to free up some cash to pursue acquisitions and invest in more growth opportunities. Investors haven't been encouraged thus far as the stock continues to trade at a low valuation; it's down close to 40% in five years.
For Verizon, its big unknown is related to SpaceX and how competitive its Starlink business may prove to be. It's a tough question to answer right now, but Verizon may face greater adversity and competition, leading to more aggressive pricing, margin pressure, and lower earnings and free cash flow.
Verizon, however, doesn't have to drastically alter its growth strategy and likely spend as heavily as Pfizer might; thus, it gets the edge based on their criteria.
The only metric that might make Pfizer look better than Verizon is dividend growth. But even then, when predicting future dividend growth, I think Verizon may be better positioned to increase its dividend faster, given its stronger financials.
While both of these stocks can be compelling dividend options for investors, I think Verizon is the far better and safer buy today.
Before you buy stock in Pfizer, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $385,055! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,228,089!
Now, it’s worth noting Stock Advisor’s total average return is 902% — a market-crushing outperformance compared to 209% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of July 1, 2026. *
David Jagielski, CPA has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool recommends Verizon Communications. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"High dividend yields in these specific names are currently a reflection of market skepticism regarding long-term cash flow sustainability rather than a simple value opportunity."
The article presents a classic 'value trap' dilemma. While both PFE and VZ offer attractive yields, investors must distinguish between structural decline and cyclical headwinds. PFE is currently in a high-stakes transition, burning cash to integrate recent M&A like Seagen to offset the post-COVID revenue cliff. Its payout ratio is misleadingly high due to non-cash charges, but the dividend safety hinges entirely on the success of its oncology pipeline. Conversely, VZ is a utility-like play burdened by massive debt and stagnant growth, facing existential threats from satellite competition. I am neutral on both; the yields are compensation for significant capital depreciation risks that haven't bottomed.
If PFE’s oncology pipeline hits a major clinical catalyst, the current 7%+ yield will be viewed as a historic entry point before a significant valuation re-rating.
"The article correctly identifies VZ as safer on current metrics but underweights Pfizer's optionality: a successful pipeline re-rating could drive 20%+ upside from here, while VZ's dividend safety is real but offers limited capital appreciation in a low-growth telecom sector."
The article's Verizon recommendation rests on two pillars: superior payout safety (67% ratio, $20B FCF vs dividends) and less capital intensity going forward. But this misses a critical structural headwind: Verizon's wireless margins are under genuine pressure from T-Mobile's aggressive pricing, and 5G capex hasn't yet normalized downward as promised. Pfizer's 40% five-year decline looks punitive, but the article conflates valuation compression with business deterioration. Post-COVID normalization was always priced in. The real question is whether Pfizer's pipeline (especially oncology) justifies re-rating—not whether it's 'safer' than VZ, which faces secular telecom commoditization.
Verizon's $20B FCF figure masks that capex intensity remains elevated; if wireless ARPU (average revenue per user) continues eroding faster than expected, that cushion evaporates faster than Pfizer's restructuring could improve its cash position.
"Pfizer's dividend growth trajectory and re-rating potential are more attractive than Verizon's once pipeline delivery and cost cuts are factored in."
The article concludes Verizon is the safer high-yield pick given its 67% payout ratio and $20B trailing FCF versus $11.5B dividends. Yet it underweights Pfizer's cost-cutting program and late-stage pipeline, which could lift FCF coverage above 100% within two years if just two of its oncology or metabolic candidates succeed. Both names trade under 9x forward earnings, but Verizon's exposure to Starlink-driven wireless price pressure is a nearer-term threat to the 6.7% yield than the article acknowledges.
Pfizer's history of value-destroying M&A and a payout ratio above 100% of reported earnings could still force a cut if restructuring savings fall short of the $4B target.
"The article understates the paired risks to dividend safety and growth in PFE and VZ, making the ‘better buy’ conclusion premature without explicit sensitivity to rate moves and pipeline outcomes."
The article fixates on yield and a sub-9x forward P/E, but the real story is risk-adjusted returns. Verizon’s 6.7% payout rests on a cash-flow profile that’s increasingly capex-heavy and levered; if 5G/margin compression or Starlink economics disappoint, cash could thin and the dividend’s safety would be questioned. Pfizer’s >100% payout ratio signals reliance on non-cash items and cost cuts, while pipeline risk and competition for vaccines and biologics cloud the long-run growth story. The 'cheap valuation' premise depends on durable FCF and approvals; a surprise miss could re-rate both names and threaten the yield.
In a rising-rate regime, these 'bond proxies' could still underperform as discount rates rise; and if either company's growth engine falters, the high yield could compress much faster than the price.
"Verizon's massive debt load makes it more vulnerable to interest rate volatility than the market currently prices in, threatening its dividend safety."
Grok and Claude are ignoring the balance sheet reality: VZ is trapped by $120B+ in net debt, making it highly sensitive to the 'higher-for-longer' interest rate environment. While they focus on FCF, they overlook that VZ’s interest expense is ballooning, which directly eats into the dividend cushion. Unlike PFE, which can pivot via R&D, VZ’s capital structure is rigid. If rates stay elevated, VZ’s debt servicing costs will force a dividend cut regardless of operational performance.
"VZ's debt is a real constraint, but the operative threat is revenue compression, not interest rates alone."
Gemini's debt argument is sound but incomplete. VZ's $120B net debt is real, but the company generates $40B+ EBITDA annually—interest coverage remains ~2.5x, manageable even at 5% rates. The sharper risk: if wireless ARPU erosion accelerates (T-Mobile's pricing war), EBITDA contracts faster than debt can be refinanced. That's the squeeze. PFE avoids this leverage trap but faces pipeline binary risk. Neither is 'safe'—they're different risk profiles masquerading as yield plays.
"VZ faces a compounding squeeze where ARPU pressure directly undermines the EBITDA cushion needed to service its rigid debt load."
Claude understates the feedback loop: sustained ARPU erosion from T-Mobile will compress the $40B EBITDA base that supports 2.5x coverage, while Gemini's $120B debt load faces higher refinancing costs. Even modest margin contraction could force accelerated deleveraging or a cut before pipeline or pricing issues fully play out.
"Verizon's dividend safety hinges more on refinancing risk and debt maturity timing than on current FCF alone; higher-for-longer rates could force a dividend cut before any near-term pipeline catalysts."
Grok, ARPU erosion is real, but the bigger lever is debt maturity risk. Verizon carries a massive refi burden in a higher-for-longer rate regime; a 2.5x coverage assumes stable EBITDA and favorable refinancings, which may not hold if capex stays elevated and financing costs rise. The dividend cushion could shrink well before any Starlink disruption or pipeline upside materializes. That nuance matters for risk-adjusted yield.
The panel is largely bearish on both PFE and VZ, with concerns about PFE's pipeline risk and VZ's debt burden and potential margin compression from wireless price pressure.
PFE's late-stage pipeline candidates potentially lifting FCF coverage above 100% within two years.
VZ's debt servicing costs forcing a dividend cut due to elevated interest rates and potential margin compression from wireless price pressure.